Batimastat

Batimastat
Clinical data
Pregnancy; category	N/A;
pleural space or abdomen
ATC code	none;
Legal status
Legal status	Never marketed;
Identifiers
	IUPAC name (2R,3S)-N4-Hydroxy-2-isobutyl-N1-[(2S)-1-(methylamino)-1-oxo-3-phenyl-2-propanyl]-3-[(2-thienylsulfanyl)methyl]succinamide;
JSmol)	Interactive image;
	SMILES O=C(NC)[C@@H](NC(=O)[C@@H]([C@@H](C(=O)NO)CSc1sccc1)CC(C)C)Cc2ccccc2;
	InChI InChI=1S/C23H31N3O4S2/c1-15(2)12-17(18(22(28)26-30)14-32-20-10-7-11-31-20)21(27)25-19(23(29)24-3)13-16-8-5-4-6-9-16/h4-11,15,17-19,30H,12-14H2,1-3H3,(H,24,29)(H,25,27)(H,26,28)/t17-,18+,19+/m1/s1; Key:XFILPEOLDIKJHX-QYZOEREBSA-N;

Batimastat (

metastatic drug that belongs to the family of drugs called angiogenesis inhibitors. It acts as a matrix metalloproteinase inhibitor (MMPI) by mimicking natural MMPI peptides. Dan Lednicer wrote about this compound in book #6 of his organic drug synthesis series.^{[citation needed}

]

Batimastat was the first MMPI that went into clinical trials. First results of a Phase I trial appeared in 1994. The drug reached Phase III but was never marketed; mainly because it couldn't be administered orally (as opposed to the newer and chemically similar MMPI marimastat), and injection into the peritoneum caused peritonitis.^[1]

It is well-known that other methods of administration include transdermal (skin lotion) as well as rectal suppositories.

References

PMID 10437989
.

This article incorporates
U.S. National Cancer Institute
.

drug article is a stub. You can help Wikipedia by expanding it.
v
t
e

[1] PMID 10437989
.

[1]